Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

creon 35.000 Ph.U (R)

Phase 3Small molecule

HHospital Clinico Universitario de Santiago

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Unresectable Pancreatic CancerRecruiting

Unresectable Pancreatic CancerPhase 3

Recruiting

Timeline

Expected Milestones

Q4 2027

ApprovedRecruiting

Unresectable Pancreatic Cancer

NCT06099119

Clinical

Trials by Indication[1]

Unresectable Pancreatic Cancer1 trial

Open Label Randomized, Multicentre, Controlled Trial of Pancreatic Enzyme Replacement Therapy (PERT) for Pancreatic Exocrine Insufficiency (PEI) in Patients With Unresectable Pancreatic Cancer. The PERTseverance Trial.

Recruiting·HHospital Clinico Universitario de Santiago·Approved·NCT06099119·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for creon 35.000 Ph.U (R). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — creon 35.000 Ph.U (R) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for creon 35.000 Ph.U (R). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospital Clinico Universitario de Santiago company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHospital Clinico Universitario de Santiago

Related News